Art. -Nr.: HY-B0112

Minoxidil

Name: Minoxidil
Brand: MedChemExpress
SKU: HY-B0112
Price: 55.00 USD
Availability: InStock
Rating: 5 (11 reviews)

(Synonyms: U10858)

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

Minoxidil (U10858) is an orally active ATP-sensitive potassium channel opener and vasodilator. Minoxidil activates Wnt/β-catenin signaling pathway, increases ERK and Akt phosphorylation, upregulates Bcl-2 and downregulates Bax, thereby promoting dermal papilla cell proliferation and hair follicle elongation. Minoxidil downregulates IL-1α, inhibits T lymphocyte activity, reduces 5α-reductase expression, and attenuates the transcriptional activity of androgen receptor. Minoxidil is converted by hair follicle sulfotransferase to Minoxidil sulfate, shortening telogen and prolonging anagen. Minoxidil can be used in research related to hair loss.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.99%
CAS. Nr.: 38304-91-5
Formel: C₉H₁₅N₅O
Molecular Weight:209.25

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Minoxidil Chemical Structure

CAS. Nr.: 38304-91-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]^[2]

IL-1α

Bax

Bcl-2

Akt

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Alle Wnt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	>10 μM Compound: MNX	Induction of cell differentiation in human HL60 cells by NBT/MTT assay Induction of cell differentiation in human HL60 cells by NBT/MTT assay	[PMID: 26832215]

In Vitro

Adaptive ImmunityApoptosisCell Cycle RegulationLocal Vascular RegulationOthers

Adaptive Immunity

Minoxidil inhibits T lymphocyte activity and inhibits interleukin-1α and prostacyclin^[1].

Apoptosis

Minoxidil (0.1-1.0 μM; 24-48 h) increases Bcl-2 and decreases Bax in human DPCs^[2].

Cell Cycle Regulation

Minoxidil reduces thymidine incorporation in proliferating hRPE after 2 days, by 56% at 1 mM, while decreasing cell number by 40%^[7].

Local Vascular Regulation

Minoxidil (20-50 µM; 12-16 hours) enhances tube formation and endothelial marker expression in human ASCs^[5].
Minoxidil increases VEGF mRNA expression in dermal papilla (DP) cells in a dose-dependent manner^[6].

Others

Minoxidil reduces the gene expression of 5α-reductase type 2 in HaCaT human keratinocytes^[1].
Minoxidil slightly increases 5α-reductase activity in dermal papilla cells from balding scalp, but has no such effect in cells from non-balding scalp^[1].
Minoxidil identifies responder and non-responder samples in the isolated hair follicle sulfotransferase assay with an OD cutoff of 0.4, with a sensitivity of 95% and a specificity of 73%^[1].
Minoxidil (0.01-1.0 μM; 5 days) promotes the proliferation of human DPCs, with 1.0 μM producing the largest reported increase (108%)^[2].
Minoxidil (0.1-1.0 μM; 1 h) activates ERK and Akt phosphorylation in human DPCs, with 1.0 μM producing the maximum increase^[2].
Minoxidil (0.01-1.0 mM; 10 days) prolongs human scalp hair follicles in organ culture, with 1.0 mM producing the maximum reported elongation (1.6 mm; 51%) in concentration-response experiments^[2].
Minoxidil increases the passage cell count of confluent neonatal foreskin keratinocytes, with activity reaching maximum at 6‑12 μg/mL; however, it cannot extend the passage number of log-phase neonatal foreskin keratinocytes on 3T3 feeder layers, and countable cells can only be maintained until passage 6^[1].
Minoxidil does not increase the 7-day cell number of NORAH 1 human keratinocytes grown without a 3T3 feeder layer under SC1, SC3, or SC8 conditions, indicating a failure to maintain the germinative pool during logarithmic-phase growth^[3].
Minoxidil increases the passage cell count of confluent human keratinocytes maintained for 4 weeks, but cholera toxin reduces this effect, consistent with a mechanism independent of cyclic adenosine monophosphate elevation^[3].
Minoxidil increases the cell number of cultured human keratinocytes across the 2-40 mM calcium range and protects against high-calcium growth inhibition, with a count of 8.30 × 10^-5[^3] at 2 mM.
Minoxidil (0.1-100 µM; 2-7 days) does not alter the proliferation of human ASCs^[5].
Minoxidil (20-50 µM; 2-4 days) increases human ASC migration in scratch wound healing and Transwell assays^[5].
Minoxidil (20-50 µM) upregulates CXCL1, PD-ECGF, and PDGF-C mRNA in human ASCs; it induces the expression of PD-ECGF and PDGF-C in human ASCs through ERK phosphorylation, whereas the upregulation of CXCL1 is independent of ERK^[5].
Minoxidil (0.01-5 mM; 7 days) inhibits the proliferation of proliferating hRPE and hTCF cells, with half-maximal effective concentrations of 1.5 mM and 2.5 mM, respectively, whereas the number of cells in density-arrested cultures changes minimally, with hRPE viability decreasing only at 5 mM^[7].
Minoxidil (5 mM; 15 minutes-7 days) produces a duration-of-exposure-dependent antiproliferative effect, with hRPE reaching half-maximal effect at 15 hours and hTCF at 80 hours^[7].
Minoxidil persistently inhibits hRPE and hTCF proliferation at 3-5 mM during a 7-day reagent-free recovery period, whereas 1-2 mM allows partial regrowth^[7].
Minoxidil (7 days) exposure of density-arrested hRPE reduces reattachment at 3-4 mM, 4 mM prevents subsequent proliferation, while 1-3 mM permits proliferation similar to the control^[7].
Minoxidil (1-5 mM) induces dose-dependent morphological changes in hRPE and hTCF, which are more pronounced in proliferating cells and show obvious reversal after removal^[7].
Minoxidil inhibits hRPE lysyl hydroxylase activity by up to 71% at 1 mM after 72 hours and does not affect prolyl hydroxylase, with the inhibition completely reversed within 48 hours after removal^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

cultured human dermal papilla cells (DPCs)
Concentration:

0.01, 0.1, 1.0 μM
Incubation Time:

5 days
Result:

Increased DPC proliferation in a dose-dependent manner: 60% at 0.01 μM, 90% at 0.1 μM, and 108% at 1.0 μM versus control in six cultures.

Western Blot Analysis^[2]

Cell Line:

cultured human DPCs
Concentration:

0.1, 1.0 μM
Incubation Time:

1 h
Result:

Activated both ERK and Akt phosphorylation in human DPCs, with 1.0 μM producing the largest increases (351% for ERK and 257% for Akt over control).

Western Blot Analysis^[2]

Cell Line:

cultured human DPCs
Concentration:

0.1, 1.0 μM
Incubation Time:

24 h and 48 h
Result:

Increased Bcl-2 and decreased Bax in human DPCs, with 1.0 μM producing the largest Bcl-2 increase at 24 h (194%) and the largest reported Bax decrease at 48 h (80%).

Cell Proliferation Assay^[5]

Cell Line:

human adipose-derived stem cells (ASCs)
Concentration:

0.1, 1, 10, 50, 100 µM (2 days live-cell assay)
20, 50, 100 µM (7 days Trypan Blue counting)
Incubation Time:

2 days; 7 days
Result:

Did not alter ASC proliferation under either condition, including at the highest dose tested.

Cell Migration Assay ^[5]

Cell Line:

human adipose-derived stem cells (ASCs)
Concentration:

20 and 50 µM
Incubation Time:

4 days (scratch assay); 2 days (Transwell assay)
Result:

Dose-dependently increased ASC migration into the scratched area over four days.
Increased the number of migratory cells in the Transwell assay compared with control.

Cell Proliferation Assay^[7]

Cell Line:

proliferating and density-arrested hRPE and hTCF
Concentration:

1, 2, 3, 4, and 5 mM (7-day pretreatment)
Incubation Time:

7 days (pretreatment); 7 days (recovery)
Result:

Treated with 1-5 mM agents for 7 days, proliferating hRPE and hTCF exhibited concentration‑dependent post‑recovery proliferation impairment, while density‑arrested counterparts maintained stable cell numbers; both cell types retained high viability except that proliferating hRPE suffered a sharp viability drop at 5 mM.

In Vivo

Nucleotide MetabolismOthers

Nucleotide Metabolism

Minoxidil shortens the telogen phase and promotes entry into the anagen phase in rats, while also increasing DNA synthesis in the anagen hair bulb^[6].

Others

Minoxidil (topical administration) shows no antiandrogenic activity in the golden hamster flank organ assay; it increases hair follicle volume in bald stump-tailed macaques while regulating the hair growth phase and resting phase, and it also shortens the resting phase and promotes earlier onset of the growth phase in rats, but cannot prolong the hair growth phase in rats^[1].
Minoxidil (5%; topical administration; five times per week) accelerates hair regrowth in the LPS-induced telogen effluvium mouse model, with a regrowth rate of 98.9% on day 13 and complete regrowth on day 17^[4].
Minoxidil (preconditioned adipose-derived stem cells; subcutaneous injection; single administration) promotes the transition of hair follicles from telogen to anagen, increases the number of mature hair follicles, and induces Ki67-positive cell proliferation in the dermal papilla in telogen C3H/HeN mice, exerting a stronger hair growth-promoting effect^[5].
Minoxidil (2%; topical administration; for 14 consecutive days) alone produces lower hair weight in C3H/HeN shaved mice than when combined with CXCL1, PD-ECGF, or PDGF-C^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6N^[4]
Dosage:

5%
Administration:

topical; five times per week; after dorsal skin shaving 25 days after plucking
Result:

Treated with the test agent, LPS‑challenged telogen effluvium model mice achieved a 98.9% hair‑regrowth area on day 13 post‑treatment initiation, and attained 100% hair‑regrowth area on days 17, 20, 24 and 27.

Animal Model:

C3H/HeN (6.5 weeks old)^[5]
Dosage:

2%
Administration:

topical; for 14 days
Result:

Conducted in a 14‑day dorsal skin hair‑growth experiment, the 2% minoxidil alone group yielded lower hair weight than groups receiving 2% minoxidil combined with CXCL1, PD‑ECGF, or PDGF‑C.

Related Protocols :

Chemical Information

CAS. Nr. 38304-91-5
Appearance Solid
Molecular Weight 209.25
Formel C₉H₁₅N₅O
Color White to off-white
SMILES

NC1=NC(N2CCCCC2)=CC(N)=[N+]1[O-]
Synonyms

U10858
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All Cell Imaging/StainingWBHistological Imaging/StainingCell Proliferation/Viability AssayIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Bioact Mater

Sustainability of functional hair follicle activity: Impact of spatially anchored multifunctional tetrahedral framework nucleic acids. [Abstract]

2025 Nov 14:57:344-357. PMID: 41323202

Minoxidil purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2025 Nov 14:57:344-357. [Abstract]

Cell proliferation assay in DPCs and HFSCs treated with DHT (500 μM) and DHT combined with Minoxidil (20 μM), tFNFs (0.25 μM), Que (20 μM), and TQC (tFNFs/Que: 0.25/20 μM) for 24 h.

Minoxidil purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2025 Nov 14:57:344-357. [Abstract]

Time-course observations of hair growth of samples at 1, 4, 7, 10, 14, 15, 18, 21, 24, and 28 days (n = 5). The results showed that Minoxidil (5%; topical application, 100 μL per application) treatment, serving as a positive control, led to gradual hair regrowth starting from day 10, with marked hair coverage observed by day 28.
Cell Stem Cell

Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo. [Abstract]

2024 Jan 4;31(1):52-70.e8. PMID: 38181751

Minoxidil purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8. [Abstract]

Representative bright-field images of ARPKD (ARPKD Epi-17) kidney organoids treated with a concentration gradient of ST034307 and Minoxidil (0.1-5 μM) in the presence of FSK for 3 days. Scale bars, 200 μm.

Minoxidil purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8. [Abstract]

Minoxidil (i.p.; once daily for 3 weeks) administered at 1 and 5 mg/kg/day reduced the calculated cystic index of ARPKD kidney organoid xenografts from host NSG mice by 18.85% and 33.93%, respectively.
J Adv Res

Targeting PLOD2 induces epithelioid differentiation and improves therapeutic response in sarcomatoid renal cell carcinoma. [Abstract]

2025 Oct 16:S2090-1232(25)00818-5. PMID: 41109566

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (0.5 mM； 48 h) led to a significant increase in the expression of epithelial differentiation markers in 786-O sccRCC cells.

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (0.25-0.5 mM; 48 h) did not cause substantial 786-O ccRCC cell death.

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (6 mg/kg; gavage) significantly reduced the Ki-67 index in sccRCC xenograft mouse models.

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (6 mg/kg; gavage) significantly reduced the tumor growth rate in sccRCC xenograft mouse models.
Phytomedicine

Deoxyshikonin from Arnebiae Radix promotes hair growth by targeting the Wnt/β-catenin signaling pathway. [Abstract]

2025 May:140:156590. PMID: 40049105
Antioxidants (Basel)

Schizochytrium sp. Extracted Lipids Prevent Alopecia by Enhancing Antioxidation and Inhibiting Ferroptosis of Dermal Papilla Cells. [Abstract]

2023 Jun 23;12(7):1332. PMID: 37507872
Cell Rep

miR-24 controls the regenerative competence of hair follicle progenitors by targeting Plk3. [Abstract]

2021 Jun 8;35(10):109225. PMID: 34107258
J Med Chem

A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy. [Abstract]

2024 Jun 27;67(12):10336-10349. PMID: 38836467
Drug Des Devel Ther

New Target for Minoxidil in the Treatment of Androgenetic Alopecia. [Abstract]

2023 Aug 24:17:2537-2547. PMID: 37645625
Dermatol Clin

2024 September 12.
Biomed Res Int

Effects of Baicalin on Alopecia and the Associated Mechanism. [Abstract]

2022 Nov 18:2022:3139123. PMID: 36440360
Sys Rev Pharm

2021;12(1):402-410.

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : 7.14 mg/mL (34.12 mM; Need ultrasonic)

DMSO : 5 mg/mL (23.89 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (4.78 mM; ultrasonic and warming and heat to 50°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.7790 mL

23.8949 mL

47.7897 mL

5 mM

0.9558 mL

4.7790 mL

9.5579 mL

10 mM

0.4779 mL

2.3895 mL

4.7790 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.71 mg/mL (3.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.71 mg/mL (3.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 0.71 mg/mL (3.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (7.1 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.5 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.5 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 1.96 mg/mL (9.37 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (23.89 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (325 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yu NY, et al. Radiofrequency Microporation Enhances Topical Minoxidil Delivery and Hair Regeneration in Androgenetic Alopecia. Pharmaceutics. 2026 Aug 28;18(9):1081.

[2]. Han JH, et al. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. Journal of dermatological science. 2004 Apr;34(2):91-8.

[3]. Kubilus J, et al. Effect of minoxidil on pre- and postconfluent keratinocytes. Journal of the American Academy of Dermatology. 1987 Mar;16(3 Pt 2):648-52.

[4]. Cohen RL, et al. Direct effects of minoxidil on epidermal cells in culture. Journal of investigative dermatology. 1984 Jan 1;82(1).

[5]. Choi N, et al. Minoxidil Promotes Hair Growth through Stimulation of Growth Factor Release from Adipose-Derived Stem Cells. International journal of molecular sciences. 2018 Feb 28;19(3):691.

[6]. Doubkova M, et al. Harnessing the biomimetic effect of macromolecular crowding in the cell-derived model of clubfoot fibrosis. Biomacromolecules. 2024 Oct 14;25(10):6485-502.

[7]. Handa JT, et al. Minoxidil inhibits ocular cell proliferation and lysyl hydroxylase activity. Investigative ophthalmology & visual science. 1993 Mar;34(3):567-75.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO / Ethanol	1 mM	4.7790 mL	23.8949 mL	47.7897 mL	119.4743 mL
DMSO / Ethanol	5 mM	0.9558 mL	4.7790 mL	9.5579 mL	23.8949 mL
	10 mM	0.4779 mL	2.3895 mL	4.7790 mL	11.9474 mL
	15 mM	0.3186 mL	1.5930 mL	3.1860 mL	7.9650 mL
	20 mM	0.2389 mL	1.1947 mL	2.3895 mL	5.9737 mL
Ethanol	25 mM	0.1912 mL	0.9558 mL	1.9116 mL	4.7790 mL
Ethanol	30 mM	0.1593 mL	0.7965 mL	1.5930 mL	3.9825 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Minoxidil

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Minoxidil

Publications Citing Use of MedChemExpress (MCE) Minoxidil

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Cellular Effect

In Vitro

In Vivo

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

In Vitro:

In Vivo:

In Vivo Dissolution Calculator

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

Your Recently Viewed Products

Minoxidil

Publications Citing Use of MedChemExpress (MCE) Minoxidil

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Beschreibung

IC50 & Target

Cellular Effect

In Vitro

In Vivo

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

In Vitro:

In Vivo:

In Vivo Dissolution Calculator

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Minoxidil Related Classifications

HY-B0112 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target